Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adding omarigliptin to metformin in adults with type 2 diabetes and inadequate glycemic control; completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Omarigliptin (omarigliptin)
• metformin (metformin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2017-03-20